» Articles » PMID: 26202291

Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease (NAFLD)

Overview
Journal Hepatol Int
Publisher Springer
Specialty Gastroenterology
Date 2015 Jul 24
PMID 26202291
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

The nonalcoholic fatty liver disease (NAFLD) is defined as the presence of hepatic steatosis, determined by either imaging or histology, in the absence of secondary causes of hepatic fat accumulation. Nonalcoholic fatty liver is defined as the presence of hepatic steatosis with no evidence of hepatocellular injury in the form of ballooning of the hepatocytes or fibrosis. NASH is defined as the presence of hepatic steatosis and inflammation with hepatocyte injury (ballooning) with or without fibrosis. Although initial epidemiological studies have focused on its prevalence in the Western countries, it is becoming increasingly clear that NAFLD is highly prevalent in the Asia Pacific region, and there may be important distinctions in its phenotype between Asia Pacific and Western countries. Of particular interest are "lean NAFLD" and the "urban-rural divide," which will be discussed in this review article. Obesity, dyslipidemia, type 2 diabetes and metabolic syndrome are established risk factors for developing NAFLD. Many other risk factors (e.g., hypothyroidism, polycystic ovary syndrome, obstructive sleep apnea, hypopituitarism and hypogonadism) for NAFLD have been described in the Western countries, but these associations are yet to be investigated adequately in the Asia Pacific region.

Citing Articles

Non-alcoholic fatty liver disease development: A multifactorial pathogenic phenomena.

Bashir A, Duseja A, De A, Mehta M, Tiwari P Liver Res. 2025; 6(2):72-83.

PMID: 39958625 PMC: 11791825. DOI: 10.1016/j.livres.2022.05.002.


A Survey Assessing Nonalcoholic Fatty Liver Disease Knowledge Among Hepatologists and Non-Hepatologists in China.

Colombo L JGH Open. 2024; 8(12):e70054.

PMID: 39659486 PMC: 11629256. DOI: 10.1002/jgh3.70054.


Metabolic associated fatty liver disease (MAFLD): assessing the knowledge and practice of primary care doctors in Seremban District, Negeri Sembilan.

Vijan K, Ali A, Mohamed Idrus N, Lourdesamy P, Margammuthu S, Perumal S Malays Fam Physician. 2024; 19:51.

PMID: 39220239 PMC: 11366277. DOI: 10.51866/oa.629.


Neuroimmune modulation in liver pathophysiology.

Zou J, Li J, Wang X, Tang D, Chen R J Neuroinflammation. 2024; 21(1):188.

PMID: 39090741 PMC: 11295927. DOI: 10.1186/s12974-024-03181-w.


The association between platelet-related parameters and nonalcoholic fatty liver disease in a metabolically healthy nonobese population.

Choe E, Kang H Sci Rep. 2024; 14(1):6118.

PMID: 38480828 PMC: 10937929. DOI: 10.1038/s41598-024-56796-7.


References
1.
Amarapurkar D, Amarapurkar A . Nonalcoholic steatohepatitis: clinicopathological profile. J Assoc Physicians India. 2001; 48(3):311-3. View

2.
Hui J, Hodge A, Farrell G, Kench J, Kriketos A, George J . Beyond insulin resistance in NASH: TNF-alpha or adiponectin?. Hepatology. 2004; 40(1):46-54. DOI: 10.1002/hep.20280. View

3.
Sung K, Ryan M, Wilson A . The severity of nonalcoholic fatty liver disease is associated with increased cardiovascular risk in a large cohort of non-obese Asian subjects. Atherosclerosis. 2008; 203(2):581-6. DOI: 10.1016/j.atherosclerosis.2008.07.024. View

4.
Song H, Lee H, Lee J, Kim J, Yim Y, Song T . Risk factors of cryptogenic hepatocellular carcinoma in patients with low body mass index or without metabolic syndrome. Korean J Intern Med. 2012; 27(1):47-52. PMC: 3295988. DOI: 10.3904/kjim.2012.27.1.47. View

5.
Armstrong M, Houlihan D, Bentham L, Shaw J, Cramb R, Olliff S . Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. J Hepatol. 2011; 56(1):234-40. DOI: 10.1016/j.jhep.2011.03.020. View